Suppr超能文献

全球范围内的血色素沉着病和献血政策:血液服务机构的调查。

Worldwide policies on haemochromatosis and blood donation: a survey among blood services.

机构信息

Centre for Evidence-Based Practice, Belgian Red Cross-Flanders, Mechelen, Belgium.

出版信息

Vox Sang. 2013 Aug;105(2):121-8. doi: 10.1111/vox.12038. Epub 2013 May 11.

Abstract

BACKGROUND AND OBJECTIVES

Haemochromatosis (HC) is a disorder of iron metabolism, requiring frequent phlebotomy to normalize high serum iron levels. There is currently no consensus relating to the eligibility of these patients to donate blood for transfusion. To gain a better understanding of the policies worldwide, a survey amongst blood services was performed.

MATERIALS AND METHODS

A web-based questionnaire was developed and distributed among 44 blood services in 41 countries to identify the different policies relating to patients with HC and blood donation.

RESULTS

Respondents from 35 blood services (80%) of 33 countries completed the questionnaire. In 24 blood services among them (69%), individuals with genetic susceptibility for HC and/or patients with HC are accepted as blood donors. In approximately one-third of these blood centres (33%), genetic carriers/patients are allowed to donate blood more frequently than regular donors. Prescription from/approval by the patient's treating physician and/or a donor physician is required in the majority of the blood services (87%). Similar policies were identified in a few countries; however, in general, the policies regarding blood donation from patients with HC remain widely variable.

CONCLUSION

The results of our survey demonstrate large differences in the blood donation policies regarding carriers/patients with HC illustrating the need for uniform evidence-based and cost-effective policies which could benefit both HC patients and the blood supply around the world.

摘要

背景与目的

血色病(HC)是一种铁代谢紊乱,需要频繁放血以将血清铁水平恢复正常。目前,对于这些患者是否有资格献血用于输血,尚无共识。为了更好地了解全球的政策,我们对血液服务机构进行了调查。

材料与方法

我们开发了一个基于网络的问卷,并分发给 41 个国家的 44 个血液服务机构,以确定与 HC 患者和献血相关的不同政策。

结果

来自 33 个国家的 35 个血液服务机构(80%)的受访者完成了问卷。在其中 24 个血液中心(69%)中,遗传易感性 HC 个体和/或 HC 患者被接受为献血者。在这些血液中心的大约三分之一(33%)中,遗传携带者/患者允许比常规献血者更频繁地献血。大多数血液服务机构(87%)需要患者治疗医生的处方/批准和/或献血医生的批准。在少数几个国家也确定了类似的政策;然而,总的来说,关于 HC 患者献血的政策仍然存在很大差异。

结论

我们的调查结果表明,HC 携带者/患者的献血政策存在很大差异,这表明需要制定统一的、基于证据的、具有成本效益的政策,这将使 HC 患者和世界各地的血液供应都受益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验